Royalty Report: Drugs, Pharmaceuticals, Biotechnology – Collection: 4366

$100.00

Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 3

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 3

Primary Industries

  • Drugs
  • Pharmaceuticals
  • Biotechnology

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 4366

License Grant
The University grants the right to use the patent rights and know-how, related to the screening and identification of Emricasan, to the Licensee.

The Licensee also has the right to grant further subLicenses to third parties and is required to pay the Licensor a portion of any such subLicense revenue.

License Property
US Patent #5672500 – Mch 2, an apoptotic cysteine protease
US Patent #5958720 – Mch 2, an apoptotic cysteine protease
US Patent #5985640 – Mch 2, an apoptotic cysteine protease
US Patent #6359127 – Mch 2, an apoptotic cysteine protease
US Patent #6407215 – Mch 2, an apoptotic cysteine protease
US Patent #6271361 – Apoptotic protease Mch 6
US Patent #6274318 – Apoptotic protease Mch 6
US Patent #6455296 – Apoptotic protease Mch 6
US Patent #6566505 – Apoptotic protease Mch 6
US Patent #6462175 – Mch 3 a novel apoptatic protease
US Patent #6686459 – Mch 3 a novel apoptatic protease
US Patent #6716960 – Mch 3 a novel apoptatic protease
US Patent #5786173 – Mch 4 and Mch 5, apoptotic protease
US Patent #5851815 – Mch 4 and Mch 5, apoptotic protease
US Patent #6287795 – Mch 4 and Mch 5, apoptotic protease
US Patent #6730779 – Mch 4 and Mch 5, apoptotic protease
US Patent #6897296 – Mch 4 and Mch 5, apoptotic protease
US Patent #6376226 – Recombinant, active caspases and uses
US Patent #6379950 – Recombinant, active caspases and uses
US Patent #6610541 – Recombinant, active caspases and uses
US Patent #6340740 – Caspase 14, an apoptotic protease
US Patent #6432628 – Caspase 14, an apoptotic protease
US Patent #6797812 – Caspase 14, an apoptotic protease
Field of Use
Emricasan is a member of a new class of drugs to modulate caspases (cell death proteases) involved in the apoptosis and inflammation pathways. Caspases are a family of cysteine proteases that become activated by apoptotic and pro-inflammatory stimuli. Emricasan is a novel and proprietary small molecule, orally active caspase inhibitor designed to block apoptosis of cells in a variety of organ systems. Emricasan has been evaluated in clinical trials to determine its usefulness as an anti-fibrotic drug to delay the progression of hepatitis and prevent the development of cirrhosis.

IPSCIO Record ID: 27633

License Grant
Licensor hereby irrevocably assigns and transfers its entire right, title and interest in and to the QCT technology, in the United States of America and all foreign countries together with all common law rights related thereto, all rights of renewal and extension, and the right to recover damages and profits for past infringements thereof, and all goodwill associated therewith, to Licensee. Such assignment shall include all patent applications, research notebooks and archived electronic files stored on any type of media or drives. Enhancements to the QCT technology shall be the property of Licensee. The Licensee is incorporated in the U.S. and based in Israel.
License Property
QCT is a rational drug design technology that is based on quantum chemistry, proprietary computational software and molecular modelling. The Quantum Mechanism Based drug creation technique combines quantum mechanics and physical organic chemistry to project estimates of essential biochemical reactions that occur at an atomic rather than molecular level. By looking at “core mechanisms” in this way it could produce a wide range of drug leads.

IPSCIO Record ID: 27616

License Grant
Licensor hereby irrevocably assigns and transfers its entire right, title and interest in and to the QCT technology, in the United States of America and all foreign countries together with all common law rights related thereto, all rights of renewal and extension, and the right to recover damages and profits for past infringements thereof, and all goodwill associated therewith, to Licensee. Such assignment shall include all patent applications, research notebooks and archived electronic files stored on any type of media or drives. Enhancements to the QCT technology shall be the property of Licensee. The Licensee is incorporated in the U.S. and based in Israel.
License Property
QCT is a rational drug design technology that is based on quantum chemistry, proprietary computational software and molecular modelling. The Quantum Mechanism Based drug creation technique combines quantum mechanics and physical organic chemistry to project estimates of essential biochemical reactions that occur at an atomic rather than molecular level. By looking at “core mechanisms” in this way it could produce a wide range of drug leads.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.